Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Court Backs GSK On Patent Rule Challenge

April 7, 2008 | A version of this story appeared in Volume 86, Issue 14

The U.S. District Court of the Eastern District of Virginia has granted summary judgment to GlaxoSmithKline in support of the drug company's challenge to final rules issued by the U.S. Patent & Trademark Office that would limit the number of patent continuations and claim applications that can be presented to PTO. GSK argued that the rules, issued last August, would impede drug discovery and development (C&EN, Dec. 17, 2007, page 19). The court ruled that PTO lacked the authority to make substantive rule changes. In a statement, PTO expressed disappointment at the court's rejection.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.